Recombinant erythropoietin (EPO) is currently indicated for use only in anemia associated
with renal transplant or end-stage renal disease. Widened indications for use in other
forms of anemia, accompanied by price reductions as a result of keen competition, have
been projected for EPO in the future.
EPO Mouse Recombinant produced in Baculovirus is a single glycosylated polypeptide chain containing 176 amino acids (27-192 aa) and having a molecular mass of 19.8kDa.
EPO is fused to a 9 amino acid His tag at C-terminus and purified by proprietary chromatographic techniques.
Erythropoietin or EPO is a hormone (glycoprotein), part of the type I cytokine group of proteins. EPO is found mainly in the kidney tissue, produced from fibroblast-like cortical interstitial cells near the proximal tubules. EPO is also present in the blood, where it acts as red cell production regulator, by the promotion of differentiation of erythroid and thereby starts hemoglobin synthesis. Furthermore, EPO has neuroprotective activity towards brain injuries & anti-apoptotic activity in different tissues.
